Ahead of its FDA approval decision on Nov 30, Vertex's kidney disease drug is being heavily scrutinized for infection risk. Local authorities and relevant stakeholders are closely monitoring the situation as fresh developments unfold on the ground. Officials noted that further verified updates and administrative measures will be shared following a detailed review.